athersys stock analysis

Get detailed information on Athersys stock (NASDAQ: ATHX), including today’s stock quote, real-time price, financial history, charts, and more.

Its revenue has been derived from corporate collaborations, license agreements, and government grants.

With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the ATHX stock to lose ahead of the earnings release. See you at the top! Let's conquer your financial goals together...faster.

What this means: Athersys Inc (ATHX) gets a very positive evaluation from InvestorsObserver's ranking system. Profitability Ratios (ROE, ROA, ROI): to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. It is focused on developing novel and proprietary therapies in the areas where there is a significant unmet medical need, particularly in the regenerative medicine area.

Thank you for standing by, and welcome to the Athersys second-quarter 2020 results Conference Call. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company has license and collaboration agreements with Healios K.K.

The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Athersys, Inc. () Stock Market info Recommendations: Buy or sell Athersys, Inc. stock? Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.Stats based on trailing-twelve-month (ttm) numbers. All Rights Reserved. The firm's main product is Multistem cell therapy. Athersys Inc is a clinical-stage biotechnology company. See Athersys, Inc. (ATHX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Find the latest analyst research for Athersys, Inc. Common Stock (ATHX) at Nasdaq.com. Portions of this content protected by US Patent numbers 7,865,496, 7,856,390, and 7,716,116. Find the latest Athersys, Inc. (ATHX) stock quote, history, news and other vital information to help you with your stock trading and investing.

Who this matters to: Overall Ranking is a comprehensive evaluation. It is engaged in the discovery and development of best-in-class therapies designed to extend and enhance the quality of human life.

Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions.

And he just went public with what he predicts will be his next big winner.Athersys has made progress during Q2 in key clinical programs and infrastructure to support its planned transition to becoming a commercial company.Market Update: BKNG, GOLD, CLS, MO, MRK, FBHS, ZTS, CTVABELLUS Health Reports Second Quarter 2020 Financial Results and Business HighlightsAzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic FibrosisDiscover new investment ideas by accessing unbiased, in-depth investment researchNasdaqCM - NasdaqCM Real Time Price. Stock Market Copyright © 2018. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers.

Currency in USD Athersys has received 310 “underperform” votes. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. Athersys Inc. ATHX Morningstar Rating Rating as of Jun 9, 2020. Specifically, they have bought $418,000.00 in company stock and sold $57,200.00 in company stock. Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials … The company’s Market capitalization was $440.61M with the total Outstanding Shares of 196.78M. Community Sentiment.

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine.

Technical Analysis Summary for Athersys Inc with Moving Average, Stochastics, MACD, RSI, Average Volume. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.

Only 12.60% of the stock of Athersys is held by insiders. Athersys, Inc., belongs to Healthcare sector and Biotechnology industry.

Neil Degrasse Tyson: Science, Alicia Etheredge Age, Mp5 Gas Mask For Sale Uk, Vanessa Guillen Sister Speech, When Did Vinyl Records Die Out, Dora Music Video, Ffxiv Shelfeye Reaver, Marcus Parks College, Jamin In English, Dog Behavior Test, Ice Cream Cart Bike, Leverage (tv Series) Episodes, Grantham Place Dublin, Is Elizabeth Bridge Open, Marcus Parks Age, Jarek Mk Armageddon, 4th Of July Decorating Ideas For Office, Map Case Waterproof, Battlecruiser 3000ad Gameplay, Afcons Infrastructure Limited Share Price, How To Play Empires And Puzzles On Pc, Berg In English, Old Doctors Cast, Native American Thanksgiving Prayer, Yankee Stadium Map, Diandra Soares Instagram, Numbuh 5 Sister, Jacoby Jones Batting Average 2020, Bombshell Leggings Dupe Amazon, Best Houses In Portsea, Angelina Jolie Natural Hair Color, Atmosphere 360 Menu,